Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition

BACKGROUND: Despite the introduction of several novel therapeutic approaches that improved survival, metastatic castration-resistant prostate cancer (mCRPC) remains an incurable disease. Herein we report the synergistic antitumor interaction between two well-known drugs used for years in clinical pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Iannelli, Federica, Roca, Maria Serena, Lombardi, Rita, Ciardiello, Chiara, Grumetti, Laura, De Rienzo, Simona, Moccia, Tania, Vitagliano, Carlo, Sorice, Angela, Costantini, Susan, Milone, Maria Rita, Pucci, Biagio, Leone, Alessandra, Di Gennaro, Elena, Mancini, Rita, Ciliberto, Gennaro, Bruzzese, Francesca, Budillon, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545949/
https://www.ncbi.nlm.nih.gov/pubmed/33032653
http://dx.doi.org/10.1186/s13046-020-01723-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545949/
https://www.ncbi.nlm.nih.gov/pubmed/33032653
http://dx.doi.org/10.1186/s13046-020-01723-7

Ejemplares similares